Exploiting p70 S6 kinase as a target for ovarian cancer

Abstract

The p70 S6 kinase (p70 S6K) is frequently active in ovarian and a wide range of cancer types, and it has a crucial role in several processes considered hallmarks of cancer. Therefore, blocking p70 S6K expression or activity may present a promising strategy for anticancer treatment. Areas covered: The current understanding of the molecular mechanisms that govern p70 S6K regulation as well as its tumorigenic effects, which are involved in the initiation and progression in ovarian cancer, in particular the emerging new role of p70 S6K in cell migration, which is a prerequisite of tumor metastasis. The p70 S6K cellular substrates and/or interacting proteins. The current state of drugs that target this kinase, either alone or in combination with other targeted agents. Expert opinion: Targeting p70 S6K through the use of small-molecule inhibitors, microRNAs and natural compounds may represent a beneficial new avenue for cancer therapy and opens new areas of investigation in p70 S6K biology. © 2012 Informa UK, Ltd.